Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Polarized XANES Monitors Femtosecond Structural Evolution of Photoexcited Vitamin B12.

Miller NA, Deb A, Alonso-Mori R, Garabato BD, Glownia JM, Kiefer LM, Koralek J, Sikorski M, Spears KG, Wiley TE, Zhu D, Kozlowski PM, Kubarych KJ, Penner-Hahn JE, Sension RJ.

J Am Chem Soc. 2017 Feb 8;139(5):1894-1899. doi: 10.1021/jacs.6b11295. Epub 2017 Jan 30.

PMID:
28135083
2.

Toward the Design of Photoresponsive Conditional Antivitamins B12: A Transient Absorption Study of an Arylcobalamin and an Alkynylcobalamin.

Miller NA, Wiley TE, Spears KG, Ruetz M, Kieninger C, Kräutler B, Sension RJ.

J Am Chem Soc. 2016 Nov 2;138(43):14250-14256. Epub 2016 Oct 24.

PMID:
27797190
3.

Photostability of Hydroxocobalamin: Ultrafast Excited State Dynamics and Computational Studies.

Wiley TE, Miller WR, Miller NA, Sension RJ, Lodowski P, Jaworska M, Kozlowski PM.

J Phys Chem Lett. 2016 Jan 7;7(1):143-7. doi: 10.1021/acs.jpclett.5b02333. Epub 2015 Dec 23.

PMID:
26655401
4.

Energy cascades, excited state dynamics, and photochemistry in cob(III)alamins and ferric porphyrins.

Rury AS, Wiley TE, Sension RJ.

Acc Chem Res. 2015 Mar 17;48(3):860-7. doi: 10.1021/ar5004016. Epub 2015 Mar 5.

PMID:
25741574
5.

Dynamics of alpha-helical subdomain rotation in the intact maltose ATP-binding cassette transporter.

Orelle C, Alvarez FJ, Oldham ML, Orelle A, Wiley TE, Chen J, Davidson AL.

Proc Natl Acad Sci U S A. 2010 Nov 23;107(47):20293-8. doi: 10.1073/pnas.1006544107. Epub 2010 Nov 8.

6.

Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study.

Evon DM, Ramcharran D, Belle SH, Terrault NA, Fontana RJ, Fried MW; Virahep-C Study Group.

Am J Gastroenterol. 2009 Dec;104(12):2949-58. doi: 10.1038/ajg.2009.528. Epub 2009 Sep 29.

PMID:
19789525
7.

Host genetics, steatosis and insulin resistance among African Americans and Caucasian Americans with hepatitis C virus genotype-1 infection.

Iuliano AD, Feingold E, Wahed AS, Kleiner DE, Belle SH, Conjeevaram HS, Zmuda J, Liang TJ, Yee LJ; Virahep-C Study.

Intervirology. 2009;52(1):49-56. doi: 10.1159/000214380. Epub 2009 Apr 25.

8.

Interleukin-6 haplotypes and the response to therapy of chronic hepatitis C virus infection.

Yee LJ, Im K, Borg B, Yang H, Liang TJ; Virahep-C Study.

Genes Immun. 2009 Jun;10(4):365-72. doi: 10.1038/gene.2009.26. Epub 2009 Apr 23.

9.

Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection.

Hoofnagle JH, Wahed AS, Brown RS Jr, Howell CD, Belle SH; Virahep-C Study Group.

J Infect Dis. 2009 Apr 15;199(8):1112-20. doi: 10.1086/597384.

PMID:
19284286
10.

Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C.

Terrault NA, Im K, Boylan R, Bacchetti P, Kleiner DE, Fontana RJ, Hoofnagle JH, Belle SH; VIRAHEP-C Study Group.

Clin Gastroenterol Hepatol. 2008 Dec;6(12):1403-11. doi: 10.1016/j.cgh.2008.08.006. Epub 2008 Aug 19.

11.

Polymorphism in the human major histocompatibility complex and early viral decline during treatment of chronic hepatitis C.

Yee LJ, Im K, Wahed AS, Bugawan T, Li J, Rhodes SL, Erlich H, Rosen HR, Liang TJ, Yang H; Virahep-C Study.

Antimicrob Agents Chemother. 2009 Feb;53(2):615-21. doi: 10.1128/AAC.00947-08. Epub 2008 Oct 13.

12.

Prospective analysis of effector and regulatory CD4+ T cells in chronic HCV patients undergoing combination antiviral therapy.

Burton JR Jr, Klarquist J, Im K, Smyk-Pearson S, Golden-Mason L, Castelblanco N, Terrault N, Rosen HR; Virahep-C Study Group.

J Hepatol. 2008 Sep;49(3):329-38. doi: 10.1016/j.jhep.2008.05.020. Epub 2008 Jun 23.

PMID:
18644644
13.

Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C.

Su X, Yee LJ, Im K, Rhodes SL, Tang Y, Tong X, Howell C, Ramcharran D, Rosen HR, Taylor MW, Liang TJ, Yang H; Virahep-C Study Group.

J Hepatol. 2008 Aug;49(2):184-91. doi: 10.1016/j.jhep.2008.04.011. Epub 2008 May 20.

14.

A pilot study of the combination of cyclosporin A and interferon alfacon-1 for the treatment of hepatitis C in previous nonresponder patients.

Cotler SJ, Morrissey MJ, Wiley TE, Layden TJ, Jensen DM.

J Clin Gastroenterol. 2003 Apr;36(4):352-5.

PMID:
12642744
15.

Spur cell anemia in alcoholic cirrhosis: cure by orthotopic liver transplantation and recurrence after liver graft failure.

Malik P, Bogetti D, Sileri P, Testa G, Blumenthal SA, Wiley TE, Layden TJ, Benedetti E.

Int Surg. 2002 Oct-Dec;87(4):201-4.

PMID:
12575799
16.

Role of echocardiography in detecting portopulmonary hypertension in liver transplant candidates.

Cotton CL, Gandhi S, Vaitkus PT, Massad MG, Benedetti E, Mrtek RG, Wiley TE.

Liver Transpl. 2002 Nov;8(11):1051-4.

17.

Hepatitis C infection in African Americans: its natural history and histological progression.

Wiley TE, Brown J, Chan J.

Am J Gastroenterol. 2002 Mar;97(3):700-6.

PMID:
11922566
18.

Amantadine's viral kinetics in chronic hepatitis C infection.

Chan J, O'Riordan K, Wiley TE.

Dig Dis Sci. 2002 Feb;47(2):438-42.

PMID:
11855564
19.

Hepatitis C: does race really matter?

Wiley TE.

Am J Gastroenterol. 2001 Aug;96(8):2292-4. No abstract available.

PMID:
11513163
20.

Risk factors for failure to meet listing requirements in liver transplant candidates with alcoholic cirrhosis.

Karman JF, Sileri P, Kamuda D, Cicalese L, Rastellini C, Wiley TE, Layden TJ, Benedetti E.

Transplantation. 2001 May 15;71(9):1210-3.

PMID:
11397951

Supplemental Content

Loading ...
Support Center